Silja Steinmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Silja Steinmann has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Schramm
Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
9 shared publications - Ansgar Wilhelm Lohse
I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
8 shared publications - Marcial Sebode
I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
5 shared publications Christian Casar
Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; I. Department of Medicine, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
3 shared publications- Samuel Huber
I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3 shared publications - Alena Laschtowitz
I. Department of Medicine, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
2 shared publications
Latest Publications
- 14 October 2026
- Published by Wolters Kluwer Health in Hepatology
Beyond the primary endpoint: Learning from “negative” AIH trials
Was not provided for this article.
- 14 October 2026
- Published by Wolters Kluwer Health in Hepatology
Beyond the primary endpoint: Learning from “negative” AIH trials
Was not provided for this article.
- Top Cited PapersOpen Access
- 19 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 71-90
Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis
- 19 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 71-90
Top Cited PapersOpen AccessIntegrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis
- Open Access
- 4 March 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (8)
Testosterone affects female CD4+ T cells in healthy individuals and autoimmune liver diseases
Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are autoimmune liver diseases with strong female predominance. They are caused by T cell–mediated injury of hepatic parenchymal cells, but the mechanisms underlying this sex bias are unknown. Here, we investigated whether testosterone contributes to T cell activation in women with PBC. Compared with sex- and age-matched healthy controls ( n = 23), cisgender (cis) women with PBC ( n = 24) demonstrated decreased testosterone serum levels and proinflammatory CD4 + T cell profile in peripheral blood. Testosterone suppressed the expression of TNF and IFN-γ by human CD4 + T cells in vitro. In trans men receiving gender-affirming hormone therapy (GAHT) ( n = 25), testosterone affected CD4 + T cell function by inhibiting Th1 and Th17 differentiation and by supporting the differentiation into regulatory Treg. Mechanistically, we provide evidence for a direct effect of testosterone on T cells using mice with T cell–specific deletion of the cytosolic androgen receptor. Supporting a role for testosterone in autoimmune liver disease, we observed an improved disease course and profound changes in T cell states in a trans man with AIH/primary sclerosing cholangitis (PSC) variant syndrome receiving GAHT. We here report a direct effect of testosterone on CD4 + T cells that may contribute to future personalized treatment strategies.
- 4 March 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (8)
Open AccessTestosterone affects female CD4+ T cells in healthy individuals and autoimmune liver diseases
Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are autoimmune liver diseases with strong female predominance. They are caused by T cell–mediated injury of hepatic parenchymal cells, but the mechanisms underlying this sex bias are unknown. Here, we investigated whether testosterone contributes to T cell activation in women with PBC. Compared with sex- and age-matched healthy controls ( n = 23), cisgender (cis) women with PBC ( n = 24) demonstrated decreased testosterone serum levels and proinflammatory CD4 + T cell profile in peripheral blood. Testosterone suppressed the expression of TNF and IFN-γ by human CD4 + T cells in vitro. In trans men receiving gender-affirming hormone therapy (GAHT) ( n = 25), testosterone affected CD4 + T cell function by inhibiting Th1 and Th17 differentiation and by supporting the differentiation into regulatory Treg. Mechanistically, we provide evidence for a direct effect of testosterone on T cells using mice with T cell–specific deletion of the cytosolic androgen receptor. Supporting a role for testosterone in autoimmune liver disease, we observed an improved disease course and profound changes in T cell states in a trans man with AIH/primary sclerosing cholangitis (PSC) variant syndrome receiving GAHT. We here report a direct effect of testosterone on CD4 + T cells that may contribute to future personalized treatment strategies.
- Open Access
- 12 November 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (3) , 101267
Liver transcriptome analysis reveals PSC-attributed gene set associated with fibrosis progression
- 12 November 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (3) , 101267
Open AccessLiver transcriptome analysis reveals PSC-attributed gene set associated with fibrosis progression
- 7 March 2024
- Published by Springer Nature in Die Innere Medizin
- Vol. 65 (4) , 1-7
Primär biliäre Cholangitis – Response-Kriterien der Erstlinientherapie und Perspektiven der Zweitlinientherapie
Zusammenfassung Hintergrund Die primär biliäre Cholangitis (PBC) ist eine chronische cholestatische Lebererkrankung, die unbehandelt zur Leberzirrhose fortschreiten kann. Die frühzeitige Diagnosestellung, Therapieeinleitung und gegebenenfalls Therapieanpassung ist daher essenziell, um eine Krankheitsprogression zu verhindern. Die Bewertung eines ausreichenden Therapieansprechens kann im klinischen Alltag eine Herausforderung darstellen, da Zeitpunkt und Grenzwerte zur Therapieevaluation in der Literatur uneinheitlich definiert sind. Ziel der Arbeit Neben der komprimierten Darstellung der leitliniengerechten Diagnostik und Erstlinientherapie soll diese Arbeit eine praktische Anleitung zur Therapieevaluation sowie Optionen der Zweitlinientherapie bei PBC darlegen. Material und Methoden Der vorliegende Beitrag basiert auf der aktuellen Leitlinie der European Association for the Study of the Liver (EASL) zum Management der PBC von 2017 sowie auf einer Literaturrecherche der Studienlage (2017–2023) mit Fokus auf die Definition des Therapieansprechens, die Risikoabschätzung der Krankheitsprogression sowie die zugelassenen und in Testung befindlichen Substanzen der Zweitlinientherapie. Ergebnisse Es existieren unterschiedliche Definitionen für das suffiziente Ansprechen auf die Therapie mit Ursodesoxycholsäure (UDCA). Die Therapieziele orientieren sich am individuellen Risiko einer Krankheitsprogression. Das geringste Risiko scheint bei einer Normalisierung der alkalischen Phosphatase (AP) sowie einem Serumbilirubinspiegel unterhalb des 0,6-fachen des oberen Grenzwerts vorzuliegen. Als erprobte Zweitlinientherapeutika stehen Obeticholsäure und Bezafibrat („off-label use“) zur Verfügung. Weitere Agonisten von Peroxisom-Proliferator-aktivierten Rezeptoren (PPAR) und Kombinationstherapien befinden sich in klinischer Testung. Schlussfolgerung Nach Therapieeinleitung sollte eine frühzeitige Evaluation des Therapieerfolgs stattfinden und bei unzureichendem Therapieansprechen gemäß dem individuellen Risikoprofil eine Zweitlinientherapie eingeleitet werden.
- 7 March 2024
- Published by Springer Nature in Die Innere Medizin
- Vol. 65 (4) , 1-7
Primär biliäre Cholangitis – Response-Kriterien der Erstlinientherapie und Perspektiven der Zweitlinientherapie
Zusammenfassung Hintergrund Die primär biliäre Cholangitis (PBC) ist eine chronische cholestatische Lebererkrankung, die unbehandelt zur Leberzirrhose fortschreiten kann. Die frühzeitige Diagnosestellung, Therapieeinleitung und gegebenenfalls Therapieanpassung ist daher essenziell, um eine Krankheitsprogression zu verhindern. Die Bewertung eines ausreichenden Therapieansprechens kann im klinischen Alltag eine Herausforderung darstellen, da Zeitpunkt und Grenzwerte zur Therapieevaluation in der Literatur uneinheitlich definiert sind. Ziel der Arbeit Neben der komprimierten Darstellung der leitliniengerechten Diagnostik und Erstlinientherapie soll diese Arbeit eine praktische Anleitung zur Therapieevaluation sowie Optionen der Zweitlinientherapie bei PBC darlegen. Material und Methoden Der vorliegende Beitrag basiert auf der aktuellen Leitlinie der European Association for the Study of the Liver (EASL) zum Management der PBC von 2017 sowie auf einer Literaturrecherche der Studienlage (2017–2023) mit Fokus auf die Definition des Therapieansprechens, die Risikoabschätzung der Krankheitsprogression sowie die zugelassenen und in Testung befindlichen Substanzen der Zweitlinientherapie. Ergebnisse Es existieren unterschiedliche Definitionen für das suffiziente Ansprechen auf die Therapie mit Ursodesoxycholsäure (UDCA). Die Therapieziele orientieren sich am individuellen Risiko einer Krankheitsprogression. Das geringste Risiko scheint bei einer Normalisierung der alkalischen Phosphatase (AP) sowie einem Serumbilirubinspiegel unterhalb des 0,6-fachen des oberen Grenzwerts vorzuliegen. Als erprobte Zweitlinientherapeutika stehen Obeticholsäure und Bezafibrat („off-label use“) zur Verfügung. Weitere Agonisten von Peroxisom-Proliferator-aktivierten Rezeptoren (PPAR) und Kombinationstherapien befinden sich in klinischer Testung. Schlussfolgerung Nach Therapieeinleitung sollte eine frühzeitige Evaluation des Therapieerfolgs stattfinden und bei unzureichendem Therapieansprechen gemäß dem individuellen Risikoprofil eine Zweitlinientherapie eingeleitet werden.
- 1 January 2024
- Published by Georg Thieme Verlag KG
Krankheitsbilder - Leber und Gallenwege
- Open Access
- 29 August 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (12) , 100898
Accuracy of controlled attenuation parameter measurement for the detection of steatosis in autoimmune liver diseases
- 29 August 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (12) , 100898
Open AccessAccuracy of controlled attenuation parameter measurement for the detection of steatosis in autoimmune liver diseases
- Open Access
- 26 April 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (5)
Immune signatures in variant syndromes of primary biliary cholangitis and autoimmune hepatitis
Background: Variant syndromes of autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) share diagnostic features of both entities, but their immunological underpinnings remain largely unexplored. Methods: We performed blood profiling of 23 soluble immune markers and immunogenetics in a cohort of 88 patients with autoimmune liver diseases (29 typical AIH, 31 typical PBC and 28 with clinically PBC/AIH variant syndromes). The association with demographical, serological and clinical features was analyzed. Results: While T and B cell receptor repertoires were highly skewed in variant syndromes compared to healthy controls, these biases were not sufficiently discriminated within the spectrum of autoimmune liver diseases. High circulating checkpoint molecules sCD25, sLAG-3, sCD86 and sTim-3 discriminated AIH from PBC on top of classical parameters such as transaminases and immunoglobulin levels. In addition, a second cluster of correlated soluble immune factors encompassing essentially TNF, IFNγ, IL12p70, sCTLA-4, sPD-1 and sPD-L1 appeared characteristic of AIH. Cases with complete biochemical responses to treatment generally showed a lower level of dysregulation. Unsupervised hierarchical clustering of classical and variant syndromes identified two pathological immunotypes consisting predominantly of either AIH or PBC cases. Variant syndromes did not form a separate group, but clustered together with either classical AIH or PBC. Clinically, patient with AIH-like variant syndromes were less likely to be able discontinue immunosuppressive treatment. Conclusions: Our analyses suggest that variants of immune mediated liver diseases may represent an immunological spectrum from PBC to AIH-like disease reflected by their pattern of soluble immune checkpoint molecules rather than separate entities.
- 26 April 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (5)
Open AccessImmune signatures in variant syndromes of primary biliary cholangitis and autoimmune hepatitis
Background: Variant syndromes of autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) share diagnostic features of both entities, but their immunological underpinnings remain largely unexplored. Methods: We performed blood profiling of 23 soluble immune markers and immunogenetics in a cohort of 88 patients with autoimmune liver diseases (29 typical AIH, 31 typical PBC and 28 with clinically PBC/AIH variant syndromes). The association with demographical, serological and clinical features was analyzed. Results: While T and B cell receptor repertoires were highly skewed in variant syndromes compared to healthy controls, these biases were not sufficiently discriminated within the spectrum of autoimmune liver diseases. High circulating checkpoint molecules sCD25, sLAG-3, sCD86 and sTim-3 discriminated AIH from PBC on top of classical parameters such as transaminases and immunoglobulin levels. In addition, a second cluster of correlated soluble immune factors encompassing essentially TNF, IFNγ, IL12p70, sCTLA-4, sPD-1 and sPD-L1 appeared characteristic of AIH. Cases with complete biochemical responses to treatment generally showed a lower level of dysregulation. Unsupervised hierarchical clustering of classical and variant syndromes identified two pathological immunotypes consisting predominantly of either AIH or PBC cases. Variant syndromes did not form a separate group, but clustered together with either classical AIH or PBC. Clinically, patient with AIH-like variant syndromes were less likely to be able discontinue immunosuppressive treatment. Conclusions: Our analyses suggest that variants of immune mediated liver diseases may represent an immunological spectrum from PBC to AIH-like disease reflected by their pattern of soluble immune checkpoint molecules rather than separate entities.
- 3 February 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , 1071-1073
Treatment of autoimmune hepatitis: Budesonide does not solve our problems
- 3 February 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , 1071-1073
Treatment of autoimmune hepatitis: Budesonide does not solve our problems
- Open Access
- 5 July 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (6) , 1532-1544
Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis
- 5 July 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (6) , 1532-1544
Open AccessInflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis